Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 10:17:771-790.
doi: 10.2147/DDDT.S399423. eCollection 2023.

The Molecular Basis of the Anti-Inflammatory Property of Astragaloside IV for the Treatment of Diabetes and Its Complications

Lin Li #  1   2   3 , Yuwei Zhang #  1   3 , Yudan Luo  1 , Xianghui Meng  1 , Guixiang Pan  4 , Han Zhang  1   2   3 , Yuhong Li  1   2   3 , Boli Zhang  1   3
Affiliations
Review

The Molecular Basis of the Anti-Inflammatory Property of Astragaloside IV for the Treatment of Diabetes and Its Complications

Lin Li et al. Drug Des Devel Ther. .

Abstract

Astragali Radix is a significant traditional Chinese medication, and has a long history of clinical application in the treatment of diabetes mellitus (DM) and its complications. AS-IV is an active saponin isolated from it. Modern pharmacological study shows that AS-IV has anti-inflammatory, anti-oxidant and immunomodulatory activities. The popular inflammatory etiology of diabetes suggests that DM is a natural immune and low-grade inflammatory disease. Pharmacological intervention of the inflammatory response may provide promising and alternative approaches for the prevention and treatment of DM and its complications. Therefore, this article focuses on the potential of AS-IV in the treatment of DM from the perspective of an anti-inflammatory molecular basis. AS-IV plays a role by regulating a variety of anti-inflammatory pathways in multiple organs, tissues and target cells throughout the body. The blockade of the NF-κB inflammatory signaling pathway may be the central link of AS-IV's anti-inflammatory effect, resulting in a reduction in the tissue structure and function damage stimulated by inflammatory factors. In addition, AS-IV can delay the onset of DM and its complications by inhibiting inflammation-related oxidative stress, fibrosis and apoptosis signals. In conclusion, AS-IV has therapeutic prospects from the perspective of reducing the inflammation of DM and its complications. An in-depth study on the anti-inflammatory mechanism of AS-IV is of great significance for the effective use of Chinese herbal medicine and the promotion of its status and influence on the world.

Keywords: anti-inflammatory property; astragaloside IV; complications; diabetes; molecular basis.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
The anti-inflammatory mechanism of AS-IV on the treatment of diabetic cardiovascular complications.
Figure 2
Figure 2
The anti-inflammatory mechanism of AS-IV on the treatment of diabetic kidney disease.
Figure 3
Figure 3
AS-IV regulates inflammatory pathways in multiple organs, tissues and target cells.
See this image and copyright information in PMC

References

    1. Carracher AM, Marathe PH, Close KL. American association of diabetes educators. J Diabetes. 2017;9(12):1054–1057. doi: 10.1111/1753-0407.12603 - DOI - PubMed
    1. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93(1):137–188. doi: 10.1152/physrev.00045.2011 - DOI - PubMed
    1. Ying W, Fu W, Lee YS, Olefsky JM. The role of macrophages in obesity-associated islet inflammation and β-cell abnormalities. Nat Rev Endocrinol. 2020;16(2):81–90. doi: 10.1038/s41574-019-0286-3 - DOI - PMC - PubMed
    1. Guzik TJ, Skiba DS, Touyz RM, Harrison DG. The role of infiltrating immune cells in dysfunctional adipose tissue. Cardiovasc Res. 2017;113(9):1009–1023. doi: 10.1093/cvr/cvx108 - DOI - PMC - PubMed
    1. von Scholten BJ, Kreiner FF, Gough SCL, von Herrath M. Current and future therapies for type 1 diabetes. Diabetologia. 2021;64(5):1037–1048. doi: 10.1007/s00125-021-05398-3 - DOI - PMC - PubMed